Operaciones de insiders

Grant, award or other acquisition pursuant to Rule 16b-3(d)

• F1 The options will vest and become exercisable in equal annual installments over three years commencing from October 19, 2026, subject to the Reporting Person's continued service through each such vesting date.

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

• F1 The options are fully vested and exercisable.

Other acquisition or disposition (describe transaction)

• F1 On July 29, 2026, RA Capital Healthcare Fund, L.P. (the Fund) entered into an Exchange Agreement with the Issuer pursuant to which the Fund exchanged, for no additional consideration, 18,030,000 shares of the Issuer's Common Stock for a pre-funded warrant exercisable for up to 18,030,000 shares of the Issuer's Common Stock at an exercise price of $0.001 per share (the Pre-Funded Warrant).
• F2 RA Capital Management, L.P. (the Adviser) is the investment manager for the Fund. The general partner of the Adviser is RA Capital Management GP, LLC (the Adviser GP), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
• F3 Held directly by the Fund.

Other acquisition or disposition (describe transaction)

• F1 On July 29, 2026, RA Capital Healthcare Fund, L.P. (the Fund) entered into an Exchange Agreement with the Issuer pursuant to which the Fund exchanged, for no additional consideration, 18,030,000 shares of the Issuer's Common Stock for a pre-funded warrant exercisable for up to 18,030,000 shares of the Issuer's Common Stock at an exercise price of $0.001 per share (the Pre-Funded Warrant).
• F4 The Pre-Funded Warrant has no expiration date and is exercisable immediately. Notwithstanding the foregoing, the Fund shall not be entitled to exercise the Pre-Funded Warrant to the extent that it would cause the aggregate number of shares of Common Stock beneficially owned by the Fund, together with its Attribution Parties (as defined in the Pre-Funded Warrant), to exceed 9.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise.
• F2 RA Capital Management, L.P. (the Adviser) is the investment manager for the Fund. The general partner of the Adviser is RA Capital Management GP, LLC (the Adviser GP), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
• F3 Held directly by the Fund.

Grant, award or other acquisition pursuant to Rule 16b-3(d)

• F1 The options will vest on the earlier of June 26, 2027 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date.

Grant, award or other acquisition pursuant to Rule 16b-3(d)

• F1 The options will vest on the earlier of June 26, 2027 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date.

Grant, award or other acquisition pursuant to Rule 16b-3(d)

• F1 The options will vest on the earlier of June 26, 2027 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date.

Grant, award or other acquisition pursuant to Rule 16b-3(d)

• F1 The options will vest on the earlier of June 26, 2027 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date.

Grant, award or other acquisition pursuant to Rule 16b-3(d)

• F1 The options will vest on the earlier of June 26, 2027 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date.

Grant, award or other acquisition pursuant to Rule 16b-3(d)

• F1 The options will vest on the earlier of June 26, 2027 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date.

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

• F1 As previously reported on a Form 3/A filed on August 28, 2025, the Reporting Person received shares of Issuer common stock as merger consideration upon the completion of the acquisition of CorHepta Pharmaceuticals, Inc. on February 21, 2025 (the Closing Date), with 338,282 shares subject to forfeiture if a certain milestone is not achieved by the first anniversary of the Closing Date. On February 21, 2026, it was determined that such milestone was not achieved, resulting in the forfeiture of all 338,282 shares. The Reporting Person received no consideration from the Issuer in connection with such forfeiture.

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

• F1 As previously reported on a Form 4 filed on August 28, 2025, the Reporting Person received shares of Issuer common stock as merger consideration upon the completion of the acquisition of CorHepta Pharmaceuticals, Inc. on February 21, 2025 (the Closing Date), with 19,089 shares subject to forfeiture if a certain milestone is not achieved by the first anniversary of the Closing Date. On February 21, 2026, it was determined that such milestone was not achieved, resulting in the forfeiture of all 19,089 shares. The Reporting Person received no consideration from the Issuer in connection with such forfeiture.

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

• F1 As previously reported on a Form 3/A filed on August 28, 2025, the Reporting Person received shares of Issuer common stock as merger consideration upon the completion of the acquisition of CorHepta Pharmaceuticals, Inc. on February 21, 2025 (the Closing Date), with 255,299 shares subject to forfeiture if a certain milestone is not achieved by the first anniversary of the Closing Date. On February 21, 2026, it was determined that such milestone was not achieved, resulting in the forfeiture of all 255,299 shares. The Reporting Person received no consideration from the Issuer in connection with such forfeiture.

Grant, award or other acquisition pursuant to Rule 16b-3(d)

• F1 The shares underlying the option shall vest and become exercisable in 36 equal monthly installments commencing from January 5, 2026, subject to the Reporting Person's continued employment through each such vesting date.

Grant, award or other acquisition pursuant to Rule 16b-3(d)

• F1 The shares underlying the option shall vest and become exercisable in 36 equal monthly installments commencing from January 5, 2026, subject to the Reporting Person's continued employment through each such vesting date.

Grant, award or other acquisition pursuant to Rule 16b-3(d)

• F1 The shares underlying the option shall vest and become exercisable in 36 equal monthly installments commencing from January 5, 2026, subject to the Reporting Person's continued employment through each such vesting date.

Open market or private purchase of non-derivative or derivative security

• F5 The securities reported herein were acquired in an underwritten public offering by the Issuer at the public offering price of $1.45 per share.
• F1 This report does not include a Series A-1 warrant to purchase 5,475,000 shares of Common Stock (the Series A-1 Warrant) or a Series B-1 warrant to purchase 10,068,120 shares of Common Stock (the Series B-1 Warrant), in each case held by Sands Capital Life Sciences Pulse Fund II, L.P. (Sands Pulse Fund II), each of which was purchased by Sands Pulse Fund II from the Issuer pursuant to that certain securities purchase agreement dated October 9, 2024 between the Issuer and, among certain other institutional and accredited investors, Sands Pulse Fund II (the Purchase Agreement).
• F2 (Continued from footnote 1) The Series A-1 Warrant is exercisable on the earlier of (a) the 75th calendar day following the initial filing date of the registration statement covering the resale of the shares of Common Stock underlying the Series A-1 warrants and Series B-1 warrants issued pursuant to the Purchase Agreement (the Warrant Initial Registration Statement) if the Securities and Exchange Commission (SEC) notifies the Issuer that it will review the Warrant Initial Registration Statement and (b) the fifth business day after the date the Issuer is notified (orally or in writing, whichever is earlier) by the SEC that the Warrant Initial Registration Statement will not be reviewed or(even if previously subject to review pursuant to clause (a) of this sentence) will not be subject to further review (the Initial Exercise Date). The Series B-1 Warrant is exercisable on the Initial Exercise Date, provided that, to the extent exercisable,
• F3 (Continued from footnote 2) the Series A-1 Warrant issued to Sands Pulse Fund II has been exercised in full either by Sands Pulse Fund II or its transferee permitted by the terms of the Series A-1 Warrant. The Series A-1 Warrant and the Series B-1 Warrant each provide that the holder of such warrant will not have the right to exercise any portion of such warrant if such holder, together with its affiliates, would beneficially own in excess of 19.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. The Reporting Persons each disclaim beneficial ownership of the shares of Common Stock underlying each of the Series A-1 Warrant and Series B-1Warrant because neither the Series A-1 Warrant nor the Series B-1 Warrant is exercisable within 60 days of this filing and such date is not determinable at this time.
• F4 Represents shares of common stock, par value $0.001, of the Issuer (Common Stock) held by Sands Pulse Fund II. Sands Capital Alternatives, LLC (Sands Alternatives) is the investment manager of Sands Pulse Fund II. Sands Capital Life Sciences Pulse Fund II-GP, L.P. (Sands Pulse GP L.P.) is the general partner of Sands Pulse Fund II. Sands Capital Life Sciences Pulse Fund II-GP, LLC (Sands Pulse GP LLC) is the general partner of Sands Pulse GP L.P. Sands Alternatives, Sands Pulse GP L.P. and Sands Pulse GPLLC each disclaim beneficial ownership of such securities except to the extent of their relative pecuniary interest therein. Frank M. Sands holds ultimate voting and investment power over these securities and may be deemed to beneficially own the securities. Mr. Sands disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.